Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612174 | 1.00 | PRMT5 (0.47) | PRMT5WDR77ESR2UCHL1NR1H2 | |
| SCHEMBL4413682 | 0.94 | NAMPT (0.47) | PRMT5WDR77UCHL1NR1H2MAPK1 | |
| SCHEMBL8191840 | 0.94 | NAMPT (0.47) | PRMT5WDR77UCHL1NR1H2MAPK1 | |
| SCHEMBL13573806 | 0.94 | NAMPT (0.47) | PRMT5WDR77UCHL1NR1H2MAPK1 | |
| SCHEMBL2100310 | 0.90 | PRMT5 (0.48) | PRMT5WDR77ESR2UCHL1NR1H2 | |
| SCHEMBL3739001 | 0.90 | PRMT5 (0.48) | PRMT5WDR77ESR2UCHL1NR1H2 | |
| SCHEMBL8262160 | 0.89 | UCHL1 (0.42) | PRMT5WDR77ESR2UCHL1NR1H2 | |
| SCHEMBL8262167 | 0.86 | PRMT5 (0.42) | PRMT5WDR77ESR2UCHL1NR1H2 | |
| SCHEMBL7850122 | 0.85 | ABHD6 (0.42) | PRMT5WDR77ABHD6NOTUMNPC1 | |
| SCHEMBL8276965 | 0.85 | UCHL1 (0.43) | PRMT5WDR77ESR2UCHL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435984-B2 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435984-B2 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2495249-A1 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | Achillion Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2125113-A2 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1773868-B1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008106130-A2 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7399749-B2 | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399749-B2 | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | RTF2, RFC5, EIF2AK2 | PRMT5 48/4885WDR77 1758/4885ESR2 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.